Global Vasculitis Treatment Market to Reach $662.4 Million by 2030
The global market for Vasculitis Treatment estimated at US$465.2 Million in the year 2022, is projected to reach a revised size of US$662.4 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Biologics, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$360.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 3.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $137.6 Million, While China is Forecast to Grow at 4.1% CAGR
The Vasculitis Treatment market in the U.S. is estimated at US$137.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$115.2 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.Select Competitors (Total 23 Featured) -
- AB Science SA
- Ablynx NV
- Acorda Therapeutics, Inc.
- Antares Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Can-Fite BioPharma Ltd.
- Celgene Corporation
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences
- Daiichi Sankyo Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Hospira, Inc.
- Idera Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Lexicon Pharmaceuticals, Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Morphotek, Inc.
- Novartis AG
- Novo Nordisk A/S
- Regeneron Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi SA
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
- Vertex Pharmaceuticals Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- Ablynx NV
- Acorda Therapeutics, Inc.
- Antares Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Can-Fite BioPharma Ltd.
- Celgene Corporation
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences
- Daiichi Sankyo Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Hospira, Inc.
- Idera Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Lexicon Pharmaceuticals, Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Morphotek, Inc.
- Novartis AG
- Novo Nordisk A/S
- Regeneron Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi SA
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
- Vertex Pharmaceuticals Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 183 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 465.2 Million |
Forecasted Market Value ( USD | $ 662.4 Million |
Compound Annual Growth Rate | 4.5% |
Regions Covered | Global |